camk2d1 Antibody

What is CAMK2D and why is it an important research target?

CAMK2D (calcium/calmodulin-dependent protein kinase type II subunit delta) is one of four isoforms of the CaMKII family, a multifunctional serine/threonine protein kinase that transmits calcium signaling. It plays crucial roles in:

• Cardiac function and pathology

• Neurodevelopment and synaptic plasticity

• Tumor initiation, angiogenesis, progression, and metastasis

Recent research highlights CAMK2D as particularly significant in BAP1-deficient malignant mesothelioma (MMe), where it is highly expressed in 70% of human MMe tissues and correlates with the loss of BAP1 expression . CAMK2D has also been identified as a potential therapeutic target in various cancers, including lung, breast, colon, and prostate cancers .

Which applications are most suitable for CAMK2D antibodies in research?

CAMK2D antibodies are versatile tools that can be employed in multiple experimental approaches:

When selecting an application, consider the specific research question, tissue type, and whether quantitative or qualitative data is needed. For instance, IHC is particularly informative when studying CAMK2D expression in relation to BAP1 status in mesothelioma tissues, as demonstrated in recent studies .

How do I select the appropriate CAMK2D antibody for my experiment?

Selection should be guided by:

• Species reactivity: Confirm the antibody reacts with your experimental model (human, mouse, rat, etc.)

• Isoform specificity: Determine if you need CAMK2D-specific detection or pan-CaMKII detection

• Application validation: Verify the antibody has been validated for your specific application

• Clonality: Consider whether monoclonal specificity or polyclonal breadth of epitope recognition is preferable

• Host species: Choose to avoid cross-reactivity issues with secondary antibodies

For example, for studying CAMK2D in human mesothelioma tissues, researchers have successfully used antibodies validated for human samples in IHC applications, which revealed the correlation between BAP1 loss and CAMK2D expression .

How can CAMK2D antibodies be used to investigate its role in BAP1-deficient malignant mesothelioma?

Recent breakthrough research identified CAMK2D as a novel therapeutic target in BAP1-deficient malignant mesothelioma. A methodological approach includes:

• Baseline expression analysis: Use CAMK2D antibodies for IHC and Western blot to assess expression levels in patient samples and cell lines

• Correlation studies: Compare CAMK2D expression with BAP1 status (present/absent) through dual immunostaining

• Functional validation: Employ CAMK2D antibodies in conjunction with the CaMKII inhibitor KN-93 to confirm target engagement

• Mechanistic investigation: Use phospho-specific antibodies to examine CAMK2D activity following various interventions

Research has demonstrated that CAMK2D is highly expressed in 94% of BAP1-negative MMe tissues compared to only 33% of BAP1-positive tissues . This correlation suggests BAP1 loss may directly or indirectly upregulate CAMK2D expression, representing a potential therapeutic vulnerability.

What experimental controls are essential when working with CAMK2D antibodies?

Rigorous control strategies are critical for ensuring reliable CAMK2D antibody results:

For CAMK2D studies in mesothelioma, researchers successfully used BAP1-knockout (BAP1-KO) and wild-type (BAP1-WT) mesothelial cell lines as genetic controls to validate antibody specificity and expression differences .

How do post-translational modifications affect CAMK2D antibody recognition?

CAMK2D undergoes several post-translational modifications that can significantly impact antibody recognition:

• Autophosphorylation: Phosphorylation at Thr287 induces conformational changes that can mask or expose epitopes. Use phospho-specific antibodies to distinguish active from inactive forms.

• Oxidation: Oxidative modification at Met281/282 activates CAMK2D independently of Ca²⁺/calmodulin, potentially altering antibody binding.

• Alternative splicing: CAMK2D has multiple splice variants affecting domain structure. Determine which variant your antibody recognizes by epitope mapping.

• S-nitrosylation: Nitric oxide-mediated modification can affect antibody recognition, particularly for antibodies targeting cysteine-rich regions.

When investigating CAMK2D in disease contexts, consider using multiple antibodies targeting different epitopes to ensure comprehensive detection regardless of modification state .

What protocol modifications improve CAMK2D antibody performance in immunohistochemistry?

Optimizing IHC protocols for CAMK2D detection requires specific adjustments:

• Antigen retrieval: Use TE buffer at pH 9.0 rather than citrate buffer for optimal epitope exposure. Heat-induced epitope retrieval at 95-97°C for 20 minutes typically yields better results than enzymatic methods .

• Blocking: Extend blocking time to 1 hour with 5% normal serum from the same species as the secondary antibody plus 1% BSA to reduce background.

• Primary antibody incubation: Overnight incubation at 4°C at dilutions between 1:50-1:200 provides optimal signal-to-noise ratio for most CAMK2D antibodies .

• Signal amplification: For tissues with low CAMK2D expression, employ tyramide signal amplification or polymer-based detection systems.

• Counterstaining: Limit hematoxylin counterstaining time to maintain visibility of low-expressing CAMK2D-positive cells.

These modifications have proven effective in studies examining CAMK2D expression in human mesothelioma tissues, allowing researchers to clearly distinguish between positive and negative samples .

What are the best approaches for validating CAMK2D antibody specificity?

Multi-modal validation ensures reliable results:

• Genetic validation: Compare staining between wild-type and CAMK2D knockout/knockdown samples. In BAP1 research, scientists validated antibody specificity using BAP1-KO and BAP1-WT isogenic cell clones .

• Peptide competition: Pre-incubate the antibody with excess immunizing peptide before application to demonstrate binding specificity.

• Orthogonal method correlation: Compare results from different detection methods (e.g., Western blot vs. IHC vs. IF) using the same antibody.

• Multiple antibody verification: Use antibodies targeting different CAMK2D epitopes and confirm consistent localization/expression patterns.

• Mass spectrometry validation: Confirm antibody-detected bands by mass spectrometry protein identification.

• Isoform specificity testing: Test the antibody against recombinant CAMK2A, CAMK2B, CAMK2G, and CAMK2D to confirm isoform specificity.

Researchers studying CAMK2D in mesothelioma employed multiple validation approaches, including genetic validation with BAP1 reconstitution experiments and correlation with CAMK2D mRNA expression data from TCGA .

How should CAMK2D antibodies be stored and handled to maintain optimal performance?

Proper storage and handling significantly impact antibody performance:

For critical experiments, compare antibody performance against a reference standard (e.g., previously successful lot) to ensure consistency .

Why might CAMK2D antibodies show inconsistent results between different tissue samples?

Several factors can contribute to variability:

• Tissue fixation differences: Overfixation can mask epitopes. Standardize fixation times (8-24 hours in 10% neutral buffered formalin) and processing protocols.

• Expression level variations: CAMK2D expression varies physiologically between tissues and pathologically between disease states. In mesothelioma research, expression varied from negative to strongly positive (3+) even within the same disease .

• Isoform or splice variant expression: Different tissues express different CAMK2D splice variants. Confirm your antibody recognizes the variant present in your tissue.

• Post-translational modifications: Phosphorylation status varies between tissues and can affect epitope accessibility. Consider using phospho-independent antibodies.

• Cross-reactivity with other CaMKII isoforms: Some antibodies may cross-react with CAMK2A, CAMK2B, or CAMK2G, particularly in tissues where multiple isoforms are expressed.

To address this, researchers studying CAMK2D in mesothelioma employed quantitative grading systems (negative, 1+, 2+, 3+) and specific staining criteria to ensure consistent interpretation across samples .

How can I troubleshoot weak or absent CAMK2D signal in Western blot analysis?

Follow this systematic approach to resolve weak signals:

• Sample preparation optimization:

  • Use RIPA buffer supplemented with protease and phosphatase inhibitors

  • Include 1 mM CaCl₂ in lysis buffer to stabilize calmodulin-binding proteins

  • Avoid boiling samples; heat at 70°C for 10 minutes instead

• Loading and transfer adjustments:

  • Increase protein loading (50-100 μg per lane)

  • Reduce methanol concentration in transfer buffer to 10%

  • Extend transfer time for high molecular weight isoforms

• Antibody optimization:

  • Reduce dilution (try 1:1000 instead of 1:5000)

  • Extend primary antibody incubation to overnight at 4°C

  • Switch to a more sensitive detection system (e.g., ECL Plus)

• Membrane treatment:

  • Try PVDF instead of nitrocellulose for better protein retention

  • Perform antigen retrieval on membranes (50 mM Tris-HCl, pH 8.0, 2% SDS, 100 mM β-mercaptoethanol, 65°C for 30 minutes)

Studies of CAMK2D expression in mesothelioma cell lines successfully detected the protein at 54-59 kDa using optimized Western blot conditions .

What factors might cause false positive results when using CAMK2D antibodies in immunohistochemistry?

False positives can arise from multiple sources:

• Cross-reactivity with other CaMKII isoforms: CAMK2A, CAMK2B, and CAMK2G share sequence homology with CAMK2D. Validate antibody specificity against all isoforms.

• Endogenous peroxidase activity: Thorough quenching (3% H₂O₂, 10 minutes) is essential, particularly in highly vascular tissues.

• Endogenous biotin: For biotin-based detection systems, use a biotin blocking step or switch to polymer-based detection.

• Non-specific Fc receptor binding: Include normal serum from the secondary antibody species in blocking buffer (5%) to reduce Fc-mediated binding.

• Edge effect artifacts: Apply hydrophobic barrier completely around tissue and maintain consistent humidity during incubations.

• Necrotic tissue binding: Exclude necrotic areas from analysis, as they often show non-specific antibody retention.

To distinguish true from false positivity, researchers studying CAMK2D in mesothelioma tissues used multiple controls, including BAP1-positive tissues as comparative references, and correlated protein expression with mRNA data from TCGA .

How can CAMK2D antibodies be employed to study its role in cancer therapeutic resistance?

Research suggests CAMK2D plays a role in therapeutic resistance, particularly to cisplatin in ovarian cancer . A methodological approach includes:

• Expression profiling: Compare CAMK2D levels in sensitive versus resistant cell lines using standardized Western blot and immunofluorescence protocols.

• Dynamic monitoring: Assess CAMK2D expression and phosphorylation status during treatment using time-course experiments with phospho-specific antibodies.

• Functional correlation: Combine CAMK2D immunodetection with apoptosis markers to establish mechanistic relationships.

• In vivo validation: Use immunohistochemistry to analyze CAMK2D expression in patient-derived xenograft models before and after treatment.

• Combinatorial approach: Evaluate CAMK2D expression/activity when combining CaMKII inhibitors (e.g., KN-93) with conventional therapeutics.

Recent research demonstrated that KN-93 displays a more potent and selective antiproliferative effect against BAP1-deficient cells than cisplatin or pemetrexed, suggesting CAMK2D inhibition could overcome resistance to conventional therapies .

What is the significance of CAMK2D in neurodevelopmental disorders and how can antibodies help characterize its role?

Recent research has implicated CAMK2D in neurodevelopmental disorders . Antibody-based investigation approaches include:

• Expression mapping: Use immunohistochemistry with CAMK2D antibodies to map expression patterns in normal versus pathological brain development.

• Variant-specific analysis: Design experiments to distinguish between wild-type and mutant CAMK2D using specific antibodies when available.

• Functional assessment: Combine CAMK2D detection with activity-dependent markers to correlate expression with neuronal function.

• Co-localization studies: Use multi-label immunofluorescence to assess CAMK2D interaction with other synaptic proteins.

• Temporal profiling: Track CAMK2D expression throughout development using standardized IHC protocols across age-matched samples.

Studies have identified individuals with neurodevelopmental disorders carrying pathogenic CAMK2D variants who display symptoms of intellectual disability, delayed speech, behavioral problems, and dilated cardiomyopathy. The majority of gain-of-function variants cause both neurological problems and dilated cardiomyopathy, while loss-of-function variants appear to induce only neurological symptoms .

How can active learning approaches improve antibody-antigen binding prediction for CAMK2D antibody development?

Active learning strategies can enhance CAMK2D antibody development through:

• Iterative epitope mapping: Use computational predictions followed by experimental validation to refine epitope accessibility models.

• Structural biology integration: Combine antibody binding data with CAMK2D structural information to improve specificity.

• Machine learning applications: Implement algorithms that analyze many-to-many relationships between antibodies and antigens to predict optimal binding pairs.

• Library-on-library screening: Employ active learning strategies to reduce the number of required antigen mutant variants by up to 35%.

• Out-of-distribution prediction: Apply specialized algorithms to predict interactions when test antibodies and antigens are not represented in training data.

Recent research has shown that active learning can significantly improve experimental efficiency in library-on-library settings and advance antibody-antigen binding prediction, reducing experimental costs and accelerating development timelines .